Astria Therapeutics Stock Performance
| ATXS Stock | USD 12.95 0.03 0.23% |
Astria Therapeutics holds a performance score of 15 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -2.42, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Astria Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Astria Therapeutics is expected to outperform it. Use Astria Therapeutics downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Astria Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Astria Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Astria Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 175.7 M | |
| Total Cashflows From Investing Activities | -191.9 M |
Astria Therapeutics Relative Risk vs. Return Landscape
If you would invest 728.00 in Astria Therapeutics on September 30, 2025 and sell it today you would earn a total of 567.00 from holding Astria Therapeutics or generate 77.88% return on investment over 90 days. Astria Therapeutics is currently generating 1.0062% in daily expected returns and assumes 4.9993% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Astria, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Astria Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Astria Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Astria Therapeutics, and traders can use it to determine the average amount a Astria Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2013
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ATXS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Astria Therapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Astria Therapeutics by adding it to a well-diversified portfolio.
Astria Therapeutics Fundamentals Growth
Astria Stock prices reflect investors' perceptions of the future prospects and financial health of Astria Therapeutics, and Astria Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Astria Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (48.31) % | ||||
| Current Valuation | 611.31 M | ||||
| Shares Outstanding | 57.08 M | ||||
| Price To Book | 5.36 X | ||||
| Price To Sales | 1,047 X | ||||
| EBITDA | (111.56 M) | ||||
| Cash And Equivalents | 102.48 M | ||||
| Cash Per Share | 7.87 X | ||||
| Total Debt | 5.35 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 2.44 X | ||||
| Cash Flow From Operations | (81.21 M) | ||||
| Earnings Per Share | (2.14) X | ||||
| Total Asset | 342.36 M | ||||
| Retained Earnings | (674.79 M) | ||||
About Astria Therapeutics Performance
Assessing Astria Therapeutics' fundamental ratios provides investors with valuable insights into Astria Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Astria Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Astri Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.Things to note about Astria Therapeutics performance evaluation
Checking the ongoing alerts about Astria Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Astria Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Astria Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (94.26 M) with profit before overhead, payroll, taxes, and interest of 706 K. | |
| Astria Therapeutics currently holds about 102.48 M in cash with (81.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.87. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Astria Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Astria Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Astria Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Astria Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Astria Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Astria Therapeutics' stock. These opinions can provide insight into Astria Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.